All In Biotech

NDA 212994 · Commave Sub

Azstarys

Dexmethylphenidate Hydrochloride, Serdexmethylphenidate Chloride · Oral

Novel

CDER novel approval, Mar 2, 2021: To treat attention deficit hyperactivity disorder

Last checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Mar 2, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

33

11 Phase 3, 3 recruiting

FAERS reports

741

114 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ABUSE, MISUSE, AND ADDICTION AZSTARYS has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including AZSTARYS, can result in overdose and death [see Overdosage ( 10 )], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection. Before prescribing AZSTARYS, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout AZSTARYS treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction [see Warnings and Precautions ( 5.1 ) and Drug Abuse and Dependence ( 9.2 )]. WARNING: ABUSE, MISUSE, AND...

What it is approved for

From the label in effect May 11, 2026.

AZSTARYS is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. Limitations of Use The use of AZSTARYS is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage [see Warnings and Precautions ( 5.7 ), Use in Specific Populations ( 8.4 )]. AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. ( 1 ) Limitations of Use The use of AZSTARYS is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage (5.7, 8.4).

Mechanism: Serdexmethylphenidate is a prodrug of dexmethylphenidate. Dexmethylphenidate HCl is a central nervous system (CNS) stimulant. The mode of therapeutic action in ADHD is not known.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • AZSTARYS · DEXMETHYLPHENIDATE HYDROCHLORIDE EQ 7.8MG BASE; SERDEXMETHYLPHENIDATE CHLORIDE EQ 39.2MG BASE · CAPSULE, ORAL · Prescription
  • AZSTARYS · DEXMETHYLPHENIDATE HYDROCHLORIDE EQ 10.4MG BASE; SERDEXMETHYLPHENIDATE CHLORIDE EQ 52.3MG BASE · CAPSULE, ORAL · Prescription
  • AZSTARYS · DEXMETHYLPHENIDATE HYDROCHLORIDE EQ 5.2MG BASE; SERDEXMETHYLPHENIDATE CHLORIDE EQ 26.1MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Dexmethylphenidate" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective91
  • therapeutic response shortened61
  • headache44
  • anxiety43
  • insomnia39
  • irritability38
  • decreased appetite34
  • nausea34
  • disturbance in attention28
  • fatigue27
  • product dose omission issue23
  • suicidal ideation23

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20201
20215
2022119
2023239
202497
2025154
2026126

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Azstarys (Serdexmethylphen/Dexmethylphen)

2024 spending

$2.1M

Beneficiaries

1,058

4,949 claims

Per beneficiary

$1,992

$13.86 per unit

View as table
YearSpending
2020$0
2021$4,249
2022$159,660
2023$1,362,149
2024$2,107,123

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 41 on PubMed

Sponsor: Commave Sub

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.